



ITW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Marina V. Backer, et al.
 Serial No. : 10/765,580
 Filed : January 27, 2004
 For : Recombinant Proteins Containing Shiga-Like Toxins and Vascular Endothelial Growth Factor Fragments
 Examiner : Robert Clinton Hayes
 Attorney Docket : 102108-300
 Group Art Unit : 1649
 Confirmation No. : 1535
 Customer No. : 27267



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on November 10, 2006.

By 
 Elizabeth A. Galletta
 Registration No. 52,941
 Attorney for Applicants

Commissioner for Patents
 U.S. Patent & Trademark Office
 P.O. Box 1450
 Alexandria, VA 22313-1450

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith is an amendment in the above-identified application. The fee has been calculated as shown below:


CLAIM AMENDMENT CALCULATION						
Total Claims	Claims Remaining after Amendment	Minus	Highest Number Previously paid for	No. of extra claims present	Rate	Additional Fee
Total Claims	25	-	25	0	x \$18.00	\$0.00
Indep. Claims	10	-	10	0	x \$84.00	\$0.00
Multiple Dependent claims(if any)					X \$280.00	\$0.00
Reduction for Small Entity (50%)						-\$0.00
TOTAL FEE						\$0.00

- [X] No additional fee is required.
- [] A check in amount of \$ _____ is attached.
- [] Charge \$ _____ to Deposit Account No. 23-1665.
Two additional copies of this transmittal are enclosed.
- [X] **Please charge any additional fees or credit overpayment to Deposit Account No. 23-1665.**
- [] A Petition and Fee for Extension of Time is enclosed.
- [X] The following additional items are enclosed:
Reply to Restriction Requirement

Respectfully submitted,

Marina V. Backer, et al.

By


Elizabeth A. Galletta
Registration No. 52,941
Attorney for Applicants

WIGGIN & DANA
One Century Tower
New Haven, CT 06508

Telephone: (203) 498-4400
Fax: (203) 782-2889

Date: November 10, 2006



THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application : Marina V. Backer, et al.
Serial No. : 10/765,580
Filed : January 27, 2004
For : Recombinant Proteins Containing
Shiga-Like Toxins and Vascular
Endothelial Growth Factor
Fragments
Examiner : Robert Clinton Hayes
Attorney Docket : 102108-300
Group Art Unit : 1649
Confirmation No. : 1535
Customer No. : 27267

* * * * *

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 10, 2006.

By

Elizabeth A. Galletta
Registration No. 52,941
Attorney for Applicant

* * * * *

RESPONSE TO RESTRICTION REQUIREMENT

U.S. Patent and Trademark Office
MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed October 12, 2006, Applicants submit the following:

Restriction Requirement

In the Restriction Requirement mailed October 12, 2006, the Examiner requested Applicants restrict the claims to one of the following groups of claims:

Group I: Claims 1-5, 11-14, 22 and 24, drawn to an isolated nucleic acid encoding a fusion protein comprising the A subunit of Shiga-like bacterial toxin and human vascular endothelial growth factor, vectors, and host cells, classified in Class 435, subclass 320.

Group II: Claims 6-10, 18, 23 and 25, drawn to fusion protein comprising the A subunit of Shiga-like bacterial toxin and human vascular endothelial growth factor, and compositions thereof, classified in Class 530, subclass 350.

Group III: Claims 15-17, drawn to methods of inactivating ribosomes in cells comprising contacting the cell with a fusion protein comprising the A subunit of Shiga-like bacterial toxin and human vascular endothelial growth factor, classified in Class 435, subclass 6.

Group IV: Claims 19-21, drawn to a method of treating a patient suffering from a pathophysiological condition that involves angiogenesis comprising administering a fusion protein comprising the A subunit of Shiga-like bacterial toxin and human vascular endothelial, classified in Class 514, subclass 12.

Applicants herein elect without traverse the claims of


Group I, e.g., Claims 1-5, 11-14, 22 and 24, for prosecution on the merits. Applicants reserve the right to file Divisional applications on the unelected claim groups pursuant to 35 USC §§120 and 121.

If the Examiner believes a telephone conference would aid in the continued prosecution of this application, the Examiner is invited and encouraged to contact Applicants' representative at the telephone number listed below.

Respectfully submitted,

Marina V. Backer, et al.

By


Elizabeth A. Galletta
Registration No. 52,941
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508

Telephone: (203) 498-4400
Fax: (203) 782-2889

Date: November 10, 2006